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Surveillance of Staphylococcus aureus infections in 3 northern remote communities of Saskatchewan 
was undertaken. Rates of methicillin-resistant infections were extremely high (146–482/10,000 
population), and most (98.2%) were caused by USA400 strains. Although USA400 prevalence has 
diminished in the United States, this strain is continuing to predominate throughout many northern 
communities in Canada. 
Over the past decade, community-associated methicillin-resistant Staphylococcus aureus 
(CA-MRSA) infections have rapidly emerged in Canada (1). These CA-MRSA strains are 
causing infections in often young otherwise healthy persons with no traditional health care–
associated risk factors (2), linked with increased illness severity and deaths (3), and now entering 
and being disseminated within health care facilities (4). In comparison to the incidence of CA-
MRSA infections in large urban centers across Canada, which has been addressed through the 
ongoing efforts of the Canadian Nosocomial Infection Surveillance Program (1), little attention 
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has been directed at the emerging problem of CA-MRSA or CA-methicillin-susceptible S. 
aureus (MSSA) in rural and northern communities of Canada. In this study, active surveillance 
was undertaken in 3 remote northern communities to assess the prevalence and effects of MRSA 
and MSSA infections. 
The Study 
Clinically significant MRSA and MSSA isolates, identified during January 2006–March 
2008, within 3 select communities (sites A–C) in northern Saskatchewan were included in this 
surveillance study. Site B also included 1 adjoining community, and sites A and B also included 
additional First Nations Reserves serviced by the community. Each site faced significant 
socioeconomic challenges. A total of 1,280 isolates, obtained from skin and soft tissue infections 
(SSTIs), urinary tract infections, upper respiratory tract infections, and lower respiratory tract 
infections, were identified as S. aureus. A high proportion of these isolates, 692 (54.1%) of 
1,280, were MRSA. Over the 2-year study period, rates of MRSA and MSSA infections in the 3 
communities ranged from 146–482/10,000 and 112–329/10,000 population, respectively. Trends 
of seasonality were apparent for MRSA infections, with the highest rates being observed in the 
third and fourth quarters of the year (Figure 1). Overall, the highest quarterly rates of MRSA and 
MSSA infections were observed at site C, with 738/10,000 and 610/10,000 population, 
respectively. 
The highest proportion of MRSA (30.4%) and MSSA (32.1%) infections were identified 
in children <10 years of age (Figure 2). Compared to MSSA infections, MRSA infections were 
statistically more likely to be causing infections in persons <30 years of age (odds ratio [OR] 
1.46, 95% confidence interval [CI] 1.14–1.86, p = 0.002) and less likely to be causing infections 
in patients >60 years of age (OR 0.33, 95% CI 0.20–0.567), p<0.001) (Figure 2). No significant 
difference was found in gender between those who acquired MRSA (46.7% male) and MSSA 
(53.3% female, 49.4% male) infections.  
Most MRSA (98.6%) and MSSA (91%) isolates were obtained from SSTIs. Further 
analysis of SSTIs, comparing where on the body the infections were seen, showed significantly 
more MRSA infections in the axillae (OR 3.04, 95% CI 1.39–6.89, p = 0.004), buttocks (OR 2.1, 
95% CI 1.27–3.49, p = 0.003), and trunk (OR 2.25, 95% CI 1.54–3.31, p = <0.001) than MSSA 
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infections. MRSA infections were significantly less likely to be found in feet (OR 0.29, 95% CI 
0.18–0.45, p<0.001), hands (OR 0.45, 95% CI 0.3–0.68, p<0.001), and face or head (OR 0.66, 
95% CI 0.48–0.90, p = 0.009). Of the additional infection sites included in this study, MSSA 
infections were statistically more likely to be identified in lower respiratory tract infections (OR 
5.6, 95% CI 1.5–24.62, p<0.05) and urinary tract infections (OR 6.76, 95% CI 2.87–16.71, 
p<0.001). 
A subset of 665 isolates were further characterized by antimicrobial drug susceptibility 
testing (Table 1). In comparison to MSSA, MRSA were significantly more likely to be 
susceptible to clindamycin, erythromycin, fusidic acid, and gentamicin, but were more likely to 
be resistant to mupirocin (Table 1). In regards to the clindamycin-resistant isolates, 3 (18.8%) of 
the 16 MRSA isolates and 73 (93.6%) of the 78 MSSA isolates were inducible. For mupirocin-
resistant isolates, all 328 of the MRSA isolates, but only 54 (70.1%) of the 77 MSSA isolates, 
displayed high level resistance (>128 μg/mL). 
Pulsed-field gel electrophoresis (PFGE) showed that most MRSA isolates (372/379, 
98.2%) were USA400. The remaining 7 MRSA isolates were identified as CMRSA10 (USA300, 
sequence type (ST) 8) (n = 5), CMRSA2 (USA100/800, ST5) (n = 1), and CMRSA8 
(EMRSA15, ST22) (n = 1). As anticipated, PFGE revealed much greater genetic diversity among 
the MSSA strains circulating in these regions than in MRSA strains. Notably, however, most 
MSSA PFGE fingerprints (79.2%) were related to highly successful Canadian epidemic MRSA 
strains, a finding that was further confirmed by using spa typing (5) (Table 2). 
MRSA isolates were more likely to harbor the genes encoding Panton-Valentine 
leukocidin than were MSSA isolates, 95.5% versus 5.2%, respectively. The PFGE and spa types 
of the 15 Panton-Valentine leukocidin–positive MSSA isolates were associated with the CA-
MRSA epidemic strain types USA400, USA300, and USA1000 (Table 2). 
Conclusions 
Rates of MSSA and MRSA infections in these 3 northern Saskatchewan communities 
(112–482 cases/10,000 population) far exceed MRSA rates reported in the neighboring provinces 
of Manitoba (≈16/10,000 population) (6) and Alberta (10.7/10,000 population) (7), as well as 
benchmark hospital rates provided by the Canadian Nosocomial Infection Surveillance Program 
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(3.43 cases/10,000 patient days) (1). The high rates of S. aureus infections in remote northern 
Saskatchewan communities has been attributed to a combination of risk factors, including 
overcrowding and poor housing conditions, inadequate hygiene, preexisting skin conditions, and 
previous high usage of antimicrobial drugs (8). 
USA400 was by far the predominant strain type in all 3 communities, accounting for 
>98% of the MRSA isolates. USA400 was first reported in Manitoba as an outbreak in the 
southern region in the late 1990s, but has since spread to the northern regions of the province 
from 2000 to 2004 (9). USA400 was thereafter seen in a central eastern Saskatchewan 
community adjacent to the Manitoba border (2) and has since disseminated as far north as 
Nunavut (10) and southwestern Alaska (11). 
Because MRSA and MSSA SSTIs tended to be identified more frequently from different 
body sites, it is appealing to speculate that CA-MRSA strains, such as USA400, might also 
colonize different body sites (e.g., axillae or intestines) more efficiently than other strains of S. 
aureus. This hypothesis coincides with a recent report in which nasal colonization was less likely 
in patients with CA-MRSA SSTIs than in those with hospital-acquired MRSA SSTIs (12). 
Intestinal carriage of S. aureus has been implicated as a risk factor for infection (13) and could 
be a strong contributor to environmental dissemination and transmission (14). This possibility 
was recently further supported by the results of a study in which the rectal carriage, but not nasal 
carriage, of USA300 was strongly associated with SSTIs in children (15). Further study is 
required to determine whether specific lineages of S. aureus are more proficient colonizers at 
non-nasal colonization sites, what host/bacteria genetic factors are involved, and whether this 
colonization plays a role in the high success of these CA-MRSA strain types. 
To address the high rates of S. aureus infections in northern Saskatchewan, physician 
treatment algorithms and educational materials have been provided throughout many northern 
communities and schools in Saskatchewan. These materials are all freely available 
(www.narp.ca) and are intended to promote proper antimicrobial drug usage and hygiene to 
diminish the spread of S. aureus disease. 
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Table 1. Broth microdilution antimicrobial susceptibilities of select MRSA and MSSA isolates, northern Canada, 2006–2008* 
Antimicrobial 
drug 
MRSA isolates, n = 379 
 
MSSA isolates, n = 286
p value OR (95% CI) % R MIC range MIC50 MIC90 % R MIC range MIC50 MIC90
Clindamycin 4.2 <0.25–>8 <0.25 <0.25  27.3 <0.25–>8 <0.25 <0.25 <0.001 0.12 (0.06–0.21)
Erythromycin 5.5 <0.25–>8 1 2  28.0 0.5–>8 2 >8 <0.001 0.15 (0.09–0.26)
Vancomycin 0 <0.25–2 1 1  0 0.5–2 1 1 NS –
SXT 0 <0.25–2 <0.25 <0.25  0 <0.25–2 <0.25 <0.25 NS –
Tetracycline 0.3 <2–>16 <2 <2  0 <2 <2 <2 NS –
Ciprofloxacin 2.4 <0.12–>8 0.5 0.5  1.7 0.25–>8 0.5 0.5 NS –
Rifampin 0 <0.25 <0.25 <0.25  0 <0.25 <0.25 <0.25 NS –
Fusidic acid 2.1 <0.06–>8 0.12 0.25  7.7 <0.06–>8 0.25 0.5 0.001 0.26 (0.1–0.62)
Linezolid 0 0.5–4 2 4  0 1–4 4 4 NS –
Gentamicin 1.6 <0.5–>16 <0.5 <0.5  8.0 <0.5–>16 <0.5 1 <0.001 0.18 (0.07–0.48)
Mupirocin 86.5 <0.12–>128 >128 >128  26.9 <0.12–>128 0.5 >128 <0.001 17.46 (11.56–26.43)
Synercid 0 <0.25–0.5 <0.25 0.5  0 <0.25–1 0.5 0.5 NS –
Nitrofurantoin 0 <32 <32 <32  0 <32 <32 <32 NS –
*Values are mg/mL except as indicated. MRSA, methicilllin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; R, resistant; OR, 
odds ratio; CI, confidence interval; MIC50, 50% minimum inhibitory concentration; MIC90, 90% inhibitory concentration; SXT, 
sulfamethoxazole/trimethoprim; NS, not significant. 
 
 
Table 2. Relationship of molecularly characterized MSSA isolates to MRSA epidemic strain types* 
MRSA PFGE epidemic types (MLST) No. (%) related MSSA isolates PVL positive Predominant spa type†
CMRSA1/USA600 (ST45) 38 (13.3) 0 t065 (n = 23)
CMRSA2/USA100/800 (ST5) 77 (26.9) 0 t311 (n = 46)
CMRSA4/USA200 (ST36) 30 (10.5) 0 t012 (n = 12)
CMRSA7/USA400 (ST1) 12 (4.2) 12 t128 (n = 8)
CMRSA10/USA300 (ST8) 3 (1.1) 2 t008 (n = 2)
USA700 (ST72) 1(0.4) 0 t148 (n = 1)
USA700 (ST97) 18 (6.3) 0 t2728 (n = 11)
USA1000 (ST59) 33 (11.5) 1 t163 (n = 27)
USA1100 (ST30) 1 (0.4) 0 t122 (n = 1)
*n = 286 MSSA isolates. MSSA, methicilin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; PVL, Panton-Valentine leukocidin; 
PFGE, pulsed-field gel electrophoresis; MLST, multilocus sequence typing; ST, sequence type. 
†Using Ridom software (www.ridom.de). 
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 Figure 1. Crude rates of community-acquired methicillin-resistant Staphylococcus aureus (A) and 
methicillin-susceptible S. aureus (B) infections per 10,000 population in 3 select communities (sites A, B, 
and C) of northern Saskatchewan, Canada.  
 
Figure 2. Age distribution of 
methicillin-resistant Staphylococc
aureus (MRSA) and methicillin-
susceptible S. aureus (MSSA) 
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